
Abogenrevenue, valuation & funding
Suzhou, ChinaFounded 2012CEO Bo Ying
Abogen Biosciences is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics for the treatment of cancer and infectious diseases.
Abogen revenue
Abogen has not published its revenue, and GetLatka has no sourced estimate yet. Know the figure? Send us a source.
Abogen valuation
Abogen is privately held, so there is no Abogen stock to buy. Investors valued it at $3.7B in its April 2021 Series B.
Abogen funding rounds & investors
Abogen has raised $792M across two rounds since 2021. The latest was a $700M Series C in August 2021.
| Date | Round | Raised | Valuation | Source |
|---|---|---|---|---|
| Aug 2021 | Series C | $700M | – | Crunchbase |
| Apr 2021 | Series B | $92M | $3.7B | Crunchbase |
| Total raised | $792M |
Abogen CEO, founders & employees
Bo Ying founded Abogen in 2012 and runs it as CEO. Abogen has 51 employees (November 2025).
- Bo YingCEO/Founder
Abogen FAQ
What is Abogen's valuation?
Investors valued Abogen at $3.7B in its April 2021 Series B, according to Crunchbase.
How much funding has Abogen raised?
Abogen has raised $792M across two funding rounds. The latest was a $700M Series C in August 2021.
Is Abogen publicly traded?
No. Abogen is a private company, so its shares aren't traded on a stock exchange.
How many employees does Abogen have?
Abogen has 51 employees as of November 2025.
Who is the CEO of Abogen?
Bo Ying is the CEO of Abogen and founded the company in 2012.
Who founded Abogen?
Bo Ying founded Abogen in 2012.
Categories
How this page is sourced
2 from public sources. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.
Updated Nov 22, 2025Data disclaimerReport a correctionClaim this profileRun Abogen? Join the podcast